Seattle Genetics today announced FDA approval for its drug Tukysa, also known as tucatinib, which fights aggressive breast cancers. Tucatinib… Read More
Chinook Therapeutics, a Vancouver, B.C.-based biotech company creating targeted therapies for kidney diseases, raised $65 million in a Series A… Read More
Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading. Quarterly… Read More
Biotech company Seattle Genetics, which develops cancer treatments, reported mixed earnings results on Thursday, its first earnings report since it closed… Read More
Seattle Genetics, a Seattle-based biotechnology company that makes the cancer therapy Adcetris, beat Wall Street expectations in its 2017 earnings… Read More
Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the… Read More
Seattle Genetics, the maker of cancer drug Adcetris, beat analyst expectations by a noticeable margin in its third-quarter earnings, reported… Read More
Seattle Genetics, a Bothell, Wash., based biotechnology company developing novel treatments for cancer, announced Monday that it has discontinued the… Read More
Bothell-based Seattle Genetics and Tokyo-based Takeda Oncology announced the success of their phase 3 clinical trial of Adcetris today, an immunotherapy drug that… Read More
Shares of Seattle Genetics stumbled on Tuesday after the Bothell-based company announced a partnership to license the Antibody-Coupled T-cell Receptor… Read More
